Amit J Sabnis
Overview
Explore the profile of Amit J Sabnis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
921
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vo K, Sabnis A, Williams P, Roy-Chowdhuri S, Patton D, Coffey B, et al.
JCO Precis Oncol
. 2024 Jun;
8:e2400103.
PMID: 38935895
Purpose: The National Cancer Institute-Children's Oncology Group (NCI-COG) Pediatric MATCH trial assigns patients age 1-21 years with refractory malignancies to phase II treatment arms of molecularly targeted therapies on the...
2.
Allegakoen D, Kwong K, Morales J, Bivona T, Sabnis A
bioRxiv
. 2023 Nov;
PMID: 37961102
Molecular chaperones including the heat-shock protein 70-kilodalton (HSP70) family and the J-domain containing protein (JDP) co-chaperones maintain homeostatic balance in eukaryotic cells through regulation of the proteome. The expansive JDP...
3.
Marinoff A, Spurr L, Fong C, Li Y, Forrest S, Ward A, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200334.
PMID: 36996377
Purpose: Osteosarcoma risk stratification, on the basis of the presence of metastatic disease at diagnosis and histologic response to chemotherapy, has remained unchanged for four decades, does not include genomic...
4.
Lazo de la Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li Y, et al.
JCO Precis Oncol
. 2022 Nov;
6():e2200390.
PMID: 36446043
Purpose: Multiple FGFR inhibitors are currently in clinical trials enrolling adults with different solid tumors, while very few enroll pediatric patients. We determined the types and frequency of alterations ()...
5.
Morales J, Allegakoen D, Garcia J, Kwong K, Sahu P, Fajardo D, et al.
JCI Insight
. 2022 Oct;
7(23).
PMID: 36282590
Oncogenic FOXO1 gene fusions drive a subset of rhabdomyosarcoma (RMS) with poor survival; to date, these cancer drivers are therapeutically intractable. To identify new therapies for this disease, we undertook...
6.
Church A, Corson L, Kao P, Imamovic-Tuco A, Reidy D, Doan D, et al.
Nat Med
. 2022 Jun;
28(8):1581-1589.
PMID: 35739269
To evaluate the clinical impact of molecular tumor profiling (MTP) with targeted sequencing panel tests, pediatric patients with extracranial solid tumors were enrolled in a prospective observational cohort study at...
7.
Desai A, Robinson G, Gauvain K, Basu E, Macy M, Maese L, et al.
Neuro Oncol
. 2022 Apr;
24(10):1776-1789.
PMID: 35395680
Background: Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1...
8.
Schienda J, Church A, Corson L, Decker B, Clinton C, Manning D, et al.
JCO Precis Oncol
. 2021 Dec;
5.
PMID: 34964003
Purpose: Molecular tumor profiling is becoming a routine part of clinical cancer care, typically involving tumor-only panel testing without matched germline. We hypothesized that integrated germline sequencing could improve clinical...
9.
Rees H, Hills N, Sabnis A, Tulpule A, Shimotake T, Goldsby R
Cancer Rep (Hoboken)
. 2021 Jul;
5(5):e1503.
PMID: 34254742
Background: Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood, but occurs infrequently in infants (<1 year). Historically, infants with RMS have worse overall survival compared to other pediatric...
10.
Heunis J, Cheah J, Sabnis A, Wustrack R
BMJ Case Rep
. 2019 Oct;
12(9).
PMID: 31570349
A 21-year-old man underwent a joint-preserving posterior acetabular resection of metastatic osteosarcoma using a three-dimensional (3D) printed model and intraoperative navigation. The combined application of these advanced technologies can allow...